Management   |   Patient advice   |   Grading

 

Adverse event management: stomatitis

Management recommendations1,2

Grade 1–2:

  • Continue GIOTRIF® (afatinib) treatment at current dose

 

Grade ≥3 or intolerable Grade 2:

  • Interrupt GIOTRIF® (afatinib), resuming treatment at a reduced dose (10 mg lower) if patient recovers to grade ≤1. Permanent discontinuation should be considered in patients who cannot tolerate 20 mg/day of GIOTRIF® (afatinib) treatment

 

All Grades:3

  • Stomatitis may be managed through palliation with: bland saline rinses, topical lidocaine anaesthetics, mucosal coating agents or analgesics
  • This choice of management should be driven by patient preference

 


Advice for patients2-4 

  • Brush teeth and gums gently with a soft toothbrush and rinse with warm salt water, after every meal and before bed. Avoid alcohol-based mouthwashes
  • Eat foods cold or at room temperature; hot and warm food can irritate a tender mouth
  • Avoid acidic, spicy or salty juices and food which may irritate the mouth. Also avoid foods which require a lot of chewing
  • Drink plenty of water and use a straw to drink liquids
  • Use lip balm or petroleum jelly for dry lips
  • When needed, numb the mouth with ice chips or flavoured ice blocks

 


Grading5

Adverse Event

Grade 1

Grade 2

Grade 3

Grade 4

Stomatitis (clinical exam)

Erythema of the mucosa

Patchy ulcerations or pseudomembranes

Confluent ulcerations or pseudomembranes; bleeding with minor trauma

Tissue necrosis; significant spontaneous bleeding; life-threatening consequences

Stomatitis (functional/symptomatic)

Upper aerodigestive tract sites: Minimal symptoms, normal diet; minimal respiratory symptoms but not interfering with function

Lower GI sites: Minimal discomfort, intervention not indicated

Upper aerodigestive tract sites: Symptomatic but can eat and swallow modified diet; respiratory symptoms interfering with function but not interfering with ADL

Lower GI sites: Symptomatic, medical intervention indicated but not interfering with ADL

Upper aerodigestive tract sites: Symptomatic and unable to adequately aliment or hydrate orally; respiratory symptoms interfering with ADL

Lower GI sites: Stool incontinence or other symptoms interfering with ADL

Symptoms associated with life-threatening consequences

Adverse Event

Stomatitis (clinical exam)

Stomatitis (functional/symptomatic)

Grade 1

Erythema of the mucosa

Upper aerodigestive tract sites: Minimal symptoms, normal diet; minimal respiratory symptoms but not interfering with function

Lower GI sites: Minimal discomfort, intervention not indicated

Grade 2

Patchy ulcerations or pseudomembranes

Upper aerodigestive tract sites: Symptomatic but can eat and swallow modified diet; respiratory symptoms interfering with function but not interfering with ADL

Lower GI sites: Symptomatic, medical intervention indicated but not interfering with ADL

Grade 3

Confluent ulcerations or pseudomembranes; bleeding with minor trauma

Upper aerodigestive tract sites: Symptomatic and unable to adequately aliment or hydrate orally; respiratory symptoms interfering with ADL

Lower GI sites: Stool incontinence or other symptoms interfering with ADL

Grade 4

Tissue necrosis; significant spontaneous bleeding; life-threatening consequences

Symptoms associated with life-threatening consequences

 

Adapted from CTCAE version 3.5


CTCAE=common terminology criteria for adverse events


References

1
GIOTRIF® (afatinib) Summary of Product Characteristics, 2018.
2
Bensinger W, et al. J Natl Compr Canc Netw 2008;6(Suppl 1):S1-21.
3
Gupta A, West H. JAMA Oncol 2016;2(10):1379.
4
Aw DC, et al. Asia-Pac J Clin Oncol 2018;14(1):23–31.
5
Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0.

Back to top

This site uses cookies to improve your browsing experience. By using this site, you agree to their use.

Cookie policy
I am a Healthcare Professional outside the US and UK

I am a Healthcare Professional outside the US and UK

Click here for international product information intended for Healthcare Professionals about afatinib for non-small-cell lung cancer treatment.

I am not a Healthcare Professional and I am outside the US and the UK

I am not a Healthcare Professional and I am outside the US and the UK

Click here for general international information about afatinib for non-small-cell lung cancer treatment.

Country-specific product information

Country-specific product information

Click here for country-specific product information intended for Healthcare Professionals about afatinib for non-small-cell lung cancer treatment.